{"id":"https://openalex.org/W3096016791","doi":"https://doi.org/10.1182/blood-2020-134676","title":"Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)","display_name":"Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3096016791","doi":"https://doi.org/10.1182/blood-2020-134676","mag":"3096016791"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-134676","doi":"https://doi.org/10.1182/blood-2020-134676","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134676","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Dandan Zheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I219193219","display_name":"Purdue University West Lafayette","ror":"https://ror.org/02dqehb95","country_code":"US","type":"education","lineage":["https://openalex.org/I219193219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dandan Zheng","raw_affiliation_strings":["Department of Pharmacy Practice, College of Pharmacy, Purdue University, West Lafayette, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy Practice, College of Pharmacy, Purdue University, West Lafayette, IN","institution_ids":["https://openalex.org/I219193219"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043764554","display_name":"Kavita Sail","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kavita Sail","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042723532","display_name":"Lindsey Elizabeth Roeker","orcid":"https://orcid.org/0000-0002-3806-059X","observed_orcids":["https://orcid.org/0000-0002-3806-059X"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lindsey E Roeker","raw_affiliation_strings":["CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067905920","display_name":"Beenish S. Manzoor","orcid":"https://orcid.org/0000-0002-0329-3465","observed_orcids":["https://orcid.org/0000-0002-0329-3465"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Beenish S Manzoor","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067536059","display_name":"Hande H. Tuncer","orcid":"https://orcid.org/0000-0001-8458-9649","observed_orcids":["https://orcid.org/0000-0001-8458-9649"]},"institutions":[{"id":"https://openalex.org/I2801756737","display_name":"Lowell General Hospital","ror":"https://ror.org/02091ng19","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801756737"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hande H. Tuncer","raw_affiliation_strings":["The Cancer Center at Lowell General Hospital, Lowell, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Cancer Center at Lowell General Hospital, Lowell, MA","institution_ids":["https://openalex.org/I2801756737"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026842309","display_name":"John Nathan Allan","orcid":"https://orcid.org/0000-0002-2088-0899","observed_orcids":["https://orcid.org/0000-0002-2088-0899"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John N. Allan","raw_affiliation_strings":["Weill Cornell Medicine, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Weill Cornell Medicine, New York, NY","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079426839","display_name":"Chaitra Shankar Ujjani","orcid":"https://orcid.org/0000-0003-1977-1510","observed_orcids":["https://orcid.org/0000-0003-1977-1510","https://orcid.org/0000-0003-2662-4826"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chaitra S. Ujjani","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055100327","display_name":"Paul M. Barr","orcid":"https://orcid.org/0000-0002-9733-401X","observed_orcids":["https://orcid.org/0000-0002-9733-401X"]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul M. Barr","raw_affiliation_strings":["Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053298824","display_name":"Toby Andrew Eyre","orcid":"https://orcid.org/0000-0002-6631-9749","observed_orcids":["https://orcid.org/0000-0002-6631-9749"]},"institutions":[{"id":"https://openalex.org/I2801179840","display_name":"Churchill Hospital","ror":"https://ror.org/009vheq40","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801179840","https://openalex.org/I4210147381"]},{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Toby A. Eyre","raw_affiliation_strings":["Churchill Hospital, Oxford University, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Churchill Hospital, Oxford University, Oxford, United Kingdom","institution_ids":["https://openalex.org/I2801179840","https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010673295","display_name":"Alan Pierre Zausner Skarbnik","orcid":"https://orcid.org/0000-0002-1276-7546","observed_orcids":["https://orcid.org/0000-0002-1276-7546"]},"institutions":[{"id":"https://openalex.org/I2802152183","display_name":"Novant Health","ror":"https://ror.org/04nv2wh79","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802152183"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan Skarbnik","raw_affiliation_strings":["Novant Health Cancer Institute, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novant Health Cancer Institute, Charlotte, NC","institution_ids":["https://openalex.org/I2802152183"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005020542","display_name":"Rajat Bannerji","orcid":"https://orcid.org/0000-0002-0770-644X","observed_orcids":["https://orcid.org/0000-0002-0770-644X"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rajat Bannerji","raw_affiliation_strings":["Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088826331","display_name":"Barbara F. Eichhorst","orcid":"https://orcid.org/0000-0001-9990-6918","observed_orcids":["https://orcid.org/0000-0001-9990-6918"]},"institutions":[{"id":"https://openalex.org/I180923762","display_name":"University of Cologne","ror":"https://ror.org/00rcxh774","country_code":"DE","type":"education","lineage":["https://openalex.org/I180923762"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Barbara Eichhorst","raw_affiliation_strings":["Department I of Internal Medicine, Center of Integrated Oncology Aachen, Bonn, Cologne, D\u00fcsseldorf; University of Cologne, Cologne, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department I of Internal Medicine, Center of Integrated Oncology Aachen, Bonn, Cologne, D\u00fcsseldorf; University of Cologne, Cologne, Germany","institution_ids":["https://openalex.org/I180923762"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042332348","display_name":"Danielle M. Brander","orcid":"https://orcid.org/0000-0002-9581-2807","observed_orcids":["https://orcid.org/0000-0002-9581-2807"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danielle M. Brander","raw_affiliation_strings":["Duke University School of Medicine, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University School of Medicine, Durham, NC","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005802271","display_name":"Simon Sharmokh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simon Sharmokh","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058473417","display_name":"Daniel Dingfeng Jiang","orcid":"https://orcid.org/0000-0001-5021-8225","observed_orcids":["https://orcid.org/0000-0001-5021-8225"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Dingfeng Jiang","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013753665","display_name":"Germ\u00e1n Pe\u00f1a","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"German Pena","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032767395","display_name":"Rajesh Kamalakar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rajesh Kamalakar","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031438549","display_name":"Nnadozie C. Emechebe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nnadozie Emechebe","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059264128","display_name":"Irina Pivneva","orcid":"https://orcid.org/0000-0003-1101-5200","observed_orcids":["https://orcid.org/0000-0003-1101-5200"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Irina Pivneva","raw_affiliation_strings":["Analysis Group, Inc., Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Inc., Montreal, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026361648","display_name":"Rebecca M. Burne","orcid":"https://orcid.org/0000-0002-3808-2430","observed_orcids":["https://orcid.org/0000-0002-3808-2430"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rebecca Burne","raw_affiliation_strings":["Analysis Group, Inc., Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Inc., Montreal, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109107770","display_name":"Annie Gu\u00e9rin","orcid":"https://orcid.org/0000-0002-9333-0812","observed_orcids":["https://orcid.org/0000-0002-9333-0812"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Annie Guerin","raw_affiliation_strings":["Analysis Group, Inc., Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Inc., Montreal, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083072418","display_name":"Anthony R. Mato","orcid":"https://orcid.org/0000-0001-8724-1875","observed_orcids":["https://orcid.org/0000-0001-8724-1875"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Mato","raw_affiliation_strings":["CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":16,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.18822754,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"19","last_page":"22"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":1.0},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/small-lymphocytic-leukemia","display_name":"small lymphocytic leukemia","score":0.9769999980926514},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.8550000190734863},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7570000290870667},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.8190000057220459},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7480000257492065},{"id":"https://openalex.org/keywords/dose-interruption","display_name":"dose interruption","score":0.7749999761581421},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.6980000138282776},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7229999899864197},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8880000114440918},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.6790000200271606},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6679999828338623},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6100000143051147},{"id":"https://openalex.org/keywords/hepatic-veno-occlusive-disease","display_name":"veno-occlusive disease","score":0.6610000133514404},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.6620000004768372},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.5730000138282776},{"id":"https://openalex.org/keywords/hyperleukocytosis","display_name":"hyperleukocytosis","score":0.4970000088214874}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.9589753150939941},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.7742098569869995},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6290404796600342},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48374128341674805},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44704392552375793},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4439883828163147}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-134676","doi":"https://doi.org/10.1182/blood-2020-134676","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134676","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2908223235","https://openalex.org/W4385955563","https://openalex.org/W4410305004","https://openalex.org/W4379981963","https://openalex.org/W3214638561","https://openalex.org/W3214703271","https://openalex.org/W4310127414","https://openalex.org/W4317632738","https://openalex.org/W3212195934","https://openalex.org/W3174856924"],"abstract_inverted_index":{"Introduction:":[0],"Venetoclax":[1,587],"has":[2],"demonstrated":[3],"deep":[4],"responses":[5,123],"and":[6,10,52,63,175,181,232,236,249,285,297,308,401,427,453,476,497,544,558,579,592,612,815,1100],"sustained":[7],"progression-free":[8],"survival":[9],"is":[11,54,645,1111],"well":[12],"tolerated":[13],"in":[14,29,41,66,70,90,208,222,230,234,239,345,359,364,622,670,700],"patients":[15],"(pts)":[16],"with":[17,154,165,265,302,448,473,494,504,601,617,638,642,655,677,691],"previously":[18],"untreated":[19],"or":[20,105,135,158,273,450,462,526,711,723,853,873,913,939,953,968,982,994,1008,1020,1033,1052,1072,1086,1244],"relapsed/refractory":[21],"(R/R)":[22],"chronic":[23],"lymphocytic":[24,26],"leukemia/small":[25],"leukemia":[27],"(CLL/SLL)":[28],"clinical":[30,71,623,652],"trials.":[31],"Some":[32],"early":[33],"studies":[34],"provided":[35,140],"initial":[36],"insight":[37],"of":[38,78,109,152,163,173,197,200,243,299,328,340,383,422,435,509,529,551,563,568,620,627,684,709,721,851,871,911,937,951,966,980,992,1006,1018,1031,1050,1070,1084,1242],"venetoclax":[39,50,60,228,254,293,317,344,353,367,376,395,572,604,656],"utilization":[40],"the":[42,127,150,195,209,218,223,244,250,337,536,650],"real-world":[43],"(RW),":[44],"but":[45],"RW":[46,628],"evidence":[47],"focusing":[48],"on":[49,705,717,847,867,907,933,947,962,976,988,1002,1014,1027,1046,1066,1080,1238],"effectiveness":[51],"safety":[53,615],"still":[55],"limited.":[56],"This":[57],"study":[58,631],"assessed":[59,131,400],"effectiveness,":[61],"safety,":[62],"treatment":[64,636],"patterns":[65,170],"CLL":[67,75,220,999],"pts":[68,95,153,164,221,264,301,333,341,385,405,428,447,459,472,482,493,503,510,518,564,570],"treated":[69],"practice.":[72,624],"Methods:":[73],"The":[74],"Collaborative":[76],"Study":[77],"Real-World":[79],"Evidence":[80],"(CORE),":[81],"a":[82,98,106,206,613],"large":[83],"multicenter":[84],"chart":[85],"review":[86],"across":[87,319],"21":[88],"institutions":[89],"4":[91],"countries,":[92],"enrolled":[93],"adult":[94],"who":[96],"initiated":[97],"first":[99],"line":[100,108],"(1L)":[101],"therapy":[102,110,189],"on/after":[103,115],"01/01/2012":[104],"new":[107],"(LOT)":[111],"for":[112,190,331,403,446,458,471,481,492,502],"R/R":[113,332,365,384,517],"CLL/SLL":[114],"02/12/2014":[116],"(current":[117],"data":[118,304],"cut":[119],"through":[120],"06/08/2020).":[121],"Clinical":[122],"were":[124,139,214,237,246,533],"abstracted":[125],"from":[126,316],"medical":[128],"records":[129],"as":[130,141,149,187,205],"by":[132,348,375,524,583],"treating":[133],"physicians":[134],"investigators":[136],"(iwCLL":[137],"criteria":[138],"reference).":[142],"Overall":[143],"response":[144,156,160,167,607],"rate":[145,589,595],"(ORR)":[146],"was":[147,185,203,256,322,334,354,369,399,410,441,466,487,590,596],"calculated":[148],"proportion":[151,339],"complete":[155],"(CR)":[157],"partial":[159],"(PR)":[161],"out":[162],"documented":[166,402],"assessments.":[168],"Treatment":[169,183],"included":[171,238],"choice":[172],"regimens":[174],"sequences,":[176],"dose":[177,179,593],"interruption,":[178],"reduction,":[180],"discontinuation.":[182],"discontinuation":[184],"defined":[186,204],"ending":[188],"any":[191],"reason(s)":[192],"other":[193],"than":[194],"completion":[196],"planned":[198],"duration":[199],"therapy.":[201],"Interruption":[202],"gap":[207],"same":[210],"LOT.":[211],"All":[212],"analyses":[213],"descriptive.":[215],"Results:":[216],"Of":[217,535],"1231":[219],"CORE":[224],"data,":[225,267],"155":[226],"received":[227,343,387],"(21":[229],"1L":[231],"134":[233],"R/R)":[235],"this":[240,630],"study.":[241],"Most":[242],"sample":[245],"male":[247],"(65%)":[248],"median":[251],"age":[252],"at":[253,902],"initiation":[255,318],"67.5":[257],"(range":[258],"37-91).":[259],"For":[260],"high-risk":[261,610],"features":[262],"among":[263],"available":[266,303],"33%":[268],"(43/132":[269],"pts)":[270,278,288],"had":[271,279,289,305,419,432,511,520,540,546],"del(17p)":[272,449,461],"TP53":[274,451,463],"mutation,":[275],"24%":[276],"(31/131":[277],"complex":[280,474,484],"karyotype":[281,475],"(\u2265":[282],"3":[283,531,545],"abnormalities),":[284],"77%":[286,442],"(61/79":[287],"unmutated":[290,495],"IGHV.":[291,506],"At":[292],"initiation,":[294],"46%,":[295],"40%,":[296],"14%":[298],"151":[300],"low,":[306],"medium,":[307],"high":[309,541,606],"tumor":[310,542],"burden,":[311,543],"respectively.":[312],"Median":[313,326],"follow-up":[314,644],"time":[315],"all":[320,569],"lines":[321],"7.0":[323],"(0.1-43.1)":[324],"months.":[325],"number":[327],"prior":[329,393],"LOT":[330],"2":[335,539],"(1-5);":[336],"largest":[338],"(36%)":[342],"2L":[346],"followed":[347,374,582],"3L":[349],"(26%).":[350],"In":[351],"1L,":[352],"most":[355],"frequently":[356],"used":[357,372],"(62%)":[358],"combination":[360],"(Figure":[361,396],"1),":[362],"while":[363],"setting":[366],"monotherapy":[368],"more":[370],"commonly":[371],"(61%)":[373],"+":[377],"rituximab":[378],"(25%;":[379],"Figure":[380],"2).":[381,397],"Majority":[382],"(63%)":[386],"Bruton's":[388],"tyrosine":[389],"kinase":[390],"inhibitors":[391],"(BTKi)":[392],"to":[394,574,647],"Response":[398],"114":[404],"(74%).":[406],"Among":[407],"these,":[408],"ORR":[409,421,434,440,465,486],"75%":[411],"(CR=40%,":[412,437,443],"PR=35%)":[413],"overall.":[414,598],"Pts":[415],"\u226565":[416],"years":[417,430],"old":[418,431],"an":[420,433,706,718,848,868,908,934,948,963,977,989,1003,1015,1028,1047,1067,1081,1103,1223,1239],"79%":[423],"(CR=41%,":[424],"PR=38%,":[425],"n=74),":[426],"<65":[429],"70%":[436],"PR=30%,":[438],"n=40).":[439],"PR=37%;":[444],"n=30)":[445],"mutation":[452],"78%":[454],"(CR=34%,":[455],"PR=44%;":[456],"n=64)":[457],"without":[460,483],"mutation.":[464],"87%":[467],"(CR=48%,":[468],"PR=39%;":[469],"n=23)":[470],"74%":[477],"(CR=32%,":[478],"PR=42%;":[479],"n=71)":[480],"karyotype.":[485],"72%":[488],"(CR=36%,":[489,499],"PR=36%;":[490],"n=53)":[491],"IGHV":[496],"91%":[498],"PR=55%;":[500],"n=11)":[501],"mutated":[505],"Overall,":[507,561],"48%":[508],"adverse":[512],"events":[513,522],"(AEs)":[514],"recorded.":[515],"Five":[516],"(3.2%)":[519],"TLS":[521,621],"(defined":[523],"Howard":[525],"Cairo-Bishop":[527],"criteria),":[528],"which":[530],"(1.9%)":[532],"clinical.":[534],"5":[537],"pts,":[538],"medium":[547],"burden.":[548],"Other":[549],"AEs":[550,575],"interest":[552,680,694],"include":[553],"neutropenia":[554,577],"(17%),":[555],"thrombocytopenia":[556,580],"(9%),":[557],"diarrhea/colitis":[559],"(5%).":[560],"32%":[562],"discontinued":[565,571],"venetoclax;":[566],"13%":[567],"due":[573],"(primarily":[576],"[n=2]":[578],"[n=2]),":[581],"disease":[584],"progression":[585],"(8%).":[586],"interruption":[588],"14%,":[591],"reduction":[594],"22%":[597],"Conclusions:":[599],"Consistent":[600],"trial":[602],"experiences,":[603],"demonstrates":[605],"rates,":[608],"including":[609],"groups,":[611],"manageable":[614],"profile":[616],"low":[618],"rates":[619],"Despite":[625],"limitations":[626],"research,":[629],"provides":[632],"useful":[633],"insights":[634],"into":[635],"practices":[637],"venetoclax.":[639],"Future":[640],"research":[641],"longer":[643],"warranted":[646],"better":[648],"understand":[649],"long-term":[651],"outcomes":[653],"associated":[654],"regimens.":[657],"Disclosures":[658],"Zheng:":[659],"AbbVie:":[660,688,880,1113,1124],"Current":[661,665,667,697],"Employment.":[662],"Sail:AbbVie":[663],"Inc.:":[664],"Employment,":[666],"equity":[668,698],"holder":[669,699],"publicly-traded":[671,701],"company.":[672,702],"Roeker:Abbott":[673],"Laboratories:":[674],"Other:":[675,689,876,895,921,927,1109,1119,1127,1135,1144,1152,1160,1168,1177,1185,1193],"spouse":[676,690],"minority":[678,692],"ownership":[679,693],";":[681],"American":[682],"Society":[683],"Hematology:":[685],"Research":[686,736,750,755,772,780,794,802,827,830,859,888,1093,1106,1114,1122,1130,1138,1147,1155,1163,1171,1180,1188,1196,1202,1210,1214,1219,1229,1248],"Funding;":[687,737,751,756,781,795,828,831,860,889,1094,1107,1123,1131,1139,1148,1156,1164,1172,1181,1189,1203,1211,1215,1220,1230,1249],".":[695],"Manzoor:AbbVie:":[696],"Tuncer:AbbVie:":[703],"Membership":[704,716,846,866,906,932,946,961,975,987,1001,1013,1026,1045,1065,1079,1237],"entity's":[707,719,849,869,909,935,949,964,978,990,1004,1016,1029,1048,1068,1082,1240],"Board":[708,720,850,870,910,936,950,965,979,991,1005,1017,1030,1049,1069,1083,1241],"Directors":[710,722,852,872,912,938,952,967,981,993,1007,1019,1032,1051,1071,1085,1243],"advisory":[712,724,854,874,914,940,954,969,983,995,1009,1021,1034,1053,1073,1087,1245],"committees;":[713,984,1010],"AstraZeneca:":[714,752,800,1011,1165],"Consultancy,":[715,749,753,758,763,767,770,779,793,801,826,845,858,887,893,904,919,925,931,960,974,986,1012,1064,1078,1117,1125,1133,1142,1150,1158,1166,1175,1183,1191,1199,1207,1226,1232,1236],"committees.":[725],"Allan:Abbvie,":[726],"Janssen,":[727,733,744],"AstraZeneca,":[728,745],"Pharmacyclics:":[729,842,1063],"Honoraria;":[730,759,764,768,879],"Celgene,":[731],"Genentech,":[732,739],"TG":[734,791,820,1234],"Therapeutics:":[735,821,840,1235],"Acerta,":[738],"Abbvie,":[740],"Sunesis,":[741],"Ascentage,":[742],"Pharmacyclics,":[743],"BeiGene:":[746,863],"Consultancy.":[747,891],"Ujjani:Gilead/Kite:":[748],"Honoraria,":[754,771,894,905,920,926,1118,1126,1134,1143,1151,1159,1167,1176,1184,1192,1200,1208,1227],"Genentech:":[757,861,1077,1206],"MorphoSys:":[760],"Consultancy;":[761,775,777,783,785,788,790,797,799,805,807,809,812,817,819,822,824,834,836,838,841,843,862,864,881,883,885,1039],"Atara:":[762],"Verastem":[765],"Oncology:":[766],"Abbvie:":[769],"Funding.":[773,803,1115,1197],"Barr:Genentech:":[774],"Merck:":[776],"Abbvie/Pharmacyclics:":[778],"Janssen:":[782,878,918,985],"Celgene:":[784,973,1190],"Seattle":[786,1043],"Genetics:":[787,1044],"Verastem:":[789,886,1060],"therapeutics:":[792],"Morphosys:":[796,844],"Gilead:":[798,857,924,1025,1157],"Brown:Novartis:":[804],"Nextcea:":[806],"Octapharma:":[808],"MEI":[810,1216],"Pharma:":[811,959,1217],"Eli":[813],"Lilly":[814],"Company:":[816,1105,1225],"Astra-Zeneca:":[818],"Sunesis:":[823],"Loxo:":[825],"Sun:":[829],"Rigel":[832],"Pharmaceuticals:":[833,945,1092],"Pfizer:":[835,1231],"Catapult:":[837],"Dynamo":[839],"committees,":[855,875,915,941,955,970,996,1022,1035,1054,1074,1088,1246],"Other;":[856,1205,1233,1251],"Invectys:":[865],"DSMC;":[877],"Kite:":[882],"Juno/Celgene:":[884],"Acerta:":[890],"Eyre:AbbVie:":[892],"travel":[896,922,928,1120,1128,1136,1145,1153,1161,1169,1178,1186,1194],"support;":[897,923],"KITE,":[898],"AZ,":[899],"Loxo":[900],"Oncology":[901],"Lilly:":[903],"Speakers":[916,942,956,971,997,1023,1036,1041,1055,1058,1061,1075,1089],"Bureau;":[917,943,957,972,998,1024,1037,1042,1056,1059,1062,1076],"support.":[929],"Skarbnik:Abbvie:":[930],"Jazz":[944],"Kite":[958],"Society:":[1000],"Alexion:":[1038],"Beigene:":[1040],"Novartis:":[1057,1182,1252],"Bureau.":[1090],"Bannerji:Regeneron":[1091],"F.":[1095,1140],"Hoffmann-La":[1096],"Roche":[1097],"Ltd/Genentech,":[1098],"Inc":[1099],"Pharmacyclics":[1101,1221],"LLC,":[1102,1222],"AbbVie":[1104,1224],"Sanofi-Pasteur:":[1108],"Spouse":[1110],"employee;":[1112],"Eichhorst:BeiGene:":[1116],"support,":[1121,1129,1137,1146,1154,1162,1170,1179,1187,1195],"Janssen-Cilag:":[1132],"Hoffmann-LaRoche:":[1141],"ArQule:":[1149],"Oxford":[1173],"Biomedica:":[1174],"Brander:Verastem:":[1198],"Other,":[1201,1209,1213,1218,1228,1247],"NCCN:":[1204,1250],"Juno/Celgene/BMS:":[1212]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}